Albiglutide does not impair the counter‐regulatory hormone response to hypoglycaemia: a randomized, double‐blind, placebo‐controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aim: To determine if the glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist albiglutide, once weekly, impairs counter‐regulatory responses during hypoglycaemia. Methods: We conducted a randomized, double‐blind, parallel, placebo‐controlled study in subjects with type 2 diabetes mellitus. A single dose of albiglutide 50 mg (n = 22) or placebo (n = 22) was administered on day 1. Glucose was clamped on day 4 (to coincide with the approximate albiglutide maximum plasma concentration) at 9.0, 5.0, 4.0, 3.3 and 2.8 mmol/l (162, 90, 72, 59.4 and 50.4 mg/dl), with a post‐clamp recovery period to 3.9 mmol/l (70 mg/dl). Hormone measurements were made at each plateau and adverse events (AEs) were recorded. Results: The counter‐regulatory hormones glucagon, epinephrine, norepinephrine, growth hormone and cortisol were appropriately suppressed when plasma glucose levels were >4.0 mmol/l (>72 mg/dl), but increased in the albiglutide and placebo groups with glucose levels <3.3 mmol/l (<59.4 mg/dl) in response to hypoglycaemia. The area under the curve geometric mean ratios (albiglutide : placebo), calculated from the clamped plateau of 4.0 mmol/l (72 mg/dl) to the glucose recovery point, were not significantly different for any of the counter‐regulatory hormones. When plasma glucose levels were >5.0 mmol/l (>90 mg/dl), albiglutide increased pancreatic β‐cell secretion of C‐peptide in a glucose‐dependent manner to a greater extent than did placebo, and it was suppressed in each group when levels were <4.0 mmol/l (<72 mg/dl). No significant difference between groups was observed in the recovery time to glucose level ≥3.9 mmol/l (≥70 mg/dl). There were no clinically relevant differences in AEs or other safety variables. Conclusions: A single 50‐mg dose of albiglutide was well tolerated and did not impair the counter‐regulatory response to hypoglycaemia. These data provide mechanistic evidence supporting the low intrinsic hypoglycaemic potential of albiglutide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · cited 2×
“When looking at the GH response to hypoglycaemia, the results were similar to those of the exenatide study [27], but different from the GLP-1 and liraglutide studies, where the rise in GH was smaller than that seen with placebo [26,28].”
ResultSecretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465 · cited 1×
“GLP-1 enhances glucose-stimulated release of insulin, which results in a low hypoglycaemic potential, inhibits glucagon release, slows gastric emptying and induces satiety [9,10].”
BackgroundPrehepatic Insulin Production in Man: Kinetic Analysis Using Peripheral Connecting Peptide Behavior*
EATON, R. P., ALLEN, R. C., SCHADE, D. S., ERICKSON, K. M., & STANDEFER, J. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-3-520 · Cited by 363
Polonsky, K. S., Licinio-Paixao, J., Given, B. D., Pugh, W., Rue, P., Galloway, J., Karrison, T., & Frank, B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112308 · Cited by 359
Pratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297 · cited 1×
“Results from previous studies have validated this approach for estimation of insulin secretion rates [23,24].”
MethodBolli, G. B., Tsalikian, E., Haymond, M. W., Cryer, P. E., & Gerich, J. E. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111359 · Cited by 108 · cited 13×
“Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from the intestinal L cells in response to food and has been shown to have a number of effects that are beneficial in patients with T2DM.”
BackgroundInfluential
Cited by
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
“However, albiglutide affected the timing of the glucagon response to hypoglycemia in a study.(160) Interestingly, long-term treatment (48 weeks) with liraglutide in the Liraglutide and Beta-cell Repair (LIBRA) trial resulted in an increase in glucagon after an oral glucose tolerance test.”
BackgroundAlbiglutide: First Global Approval
Poole, R. M., & Nowlan, M. L. (2014) · Drugs · doi:10.1007/s40265-014-0228-2 · Cited by 49
Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist
Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J., Zhi, H., & Reinhardt, R. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2836 · Cited by 41
Self-citationKorsatko, S., Jensen, L., Brunner, M., Sach‐Friedl, S., Tarp, M. D., Holst, A. G., Heller, S. R., & Pieber, T. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13422 · Cited by 29
Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
Cignarelli, A., Genchi, V. A., Le Grazie, G., Caruso, I., Marrano, N., Biondi, G., D’Oria, R., Sorice, G. P., Natalicchio, A., Perrini, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.846903 · Cited by 24
Potential approaches to prevent hypoglycemia-associated autonomic failure
Lontchi-Yimagou, E., You, J. Y., Carey, M., Gabriely, I., Shamoon, H., & Hawkins, M. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000582 · Cited by 12
Metadata
- Authors
- Hompesch, M., Jones‐Leone, A., Carr, M. C., Matthews, J., Zhi, H., Young, M., Morrow, L., & Reinhardt, R. R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-10-26
- Volume
- 17
- Issue
- 1
- Pages
- 82-90
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2005874129
- Cited by
- 31
- References
- 8
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.